Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Millendo Therapeutics, Inc.

http://millendo.com/

Latest From Millendo Therapeutics, Inc.

Levo Product Joins List Of Prader-Willi Syndrome Trial Failures

Attempts at developing an effective therapy for PWS, and the abnormal desire for food associated with the rare disorder, have been fruitless but Levo Therapeutics' enthusiasm for LV-101 remains high, despite a Phase III setback.

Rare Diseases Clinical Trials

Scrip Asks… What Does 2020 Hold For Biopharma? Part 2: Business And Investment

Executives and analysts predict trends spanning M&A, leadership diversity, curative gene therapy commercialization, biosimilars strategy and more. Expect technology innovation to continue to drive investment and deal making in biopharma.

Commercial Business Strategies

Alizé Pharma 3 Raises €67m To Build ‘Fully Fledged’ Biotech

The Series A financing positions Alizé to take a rival to Shire’s Natpara through to clinical proof of concept over the next few years.

Financing StartUps and SMEs

Start-Up Spruce Repurposes Lilly Drug For Genetic Adrenal Condition

Emerging Company Profile: Spruce and Neurocrine are both testing CRF-R1 antagonists for the orphan disease congenital adrenal hyperplasia, with Phase II data coming soon.

StartUps and SMEs Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Atterocor, Inc.
    • Alize Pharma
    • OvaScience, Inc.
UsernamePublicRestriction

Register